Is medtech behind the curve on value-based care?

Share

value-based care behind the curve Vennli

[Image from Unsplash

Less than 60% of healthcare professionals think medical device brands meet their patient outcomes expectations – an important part of value-based care, according to a new survey from analytics platform company Vennli.

“With the changes occurring in value-based healthcare model, healthcare providers are subject to more scrutiny than ever before. … Providers will put pressure on medical companies to develop products that help them improve patient outcomes,” Rachel Mele, general manager of healthcare at Vennli (South Bend, Ind.), said in an emailed statement.

Value-based care involves public and private health insurers rewarding and penalizing healthcare systems and doctors based on how effectively and efficiently they manage their patient populations. CMS administrator Seema Verma has said she wants more of it, though the agency has also cut a trio of bundled payment pilot programs meant to lower healthcare costs and improve outcomes.

Medtronic CEO Omar Ishrak said last month that a vast change of thinking is needed for the industry to adapt to the future. “Right now, medical technology is paid on the promise of the change of an outcome, but if something goes wrong, and the procedure must be done again, we get paid again – so there is a lack of accountability,” Ishrak said.

The Vennli data – collected in 45 Vennli healthcare industry studies – included responses from more than 9,000 U.S.-based healthcare professionals including physicians, dentists and other clinicians.

The top five factors for healthcare professionals when they were purchasing medical devices included:

  • Consistent outcomes (94%);
  • Positive patient outcomes (93%);
  • Durability (88%);
  • Easy to use (86%);
  • Efficacy (86%).
How do you know your technology is disruptive enough to break conventional wisdom?

textadimage Stan Rowe knows a little something about bringing disruptive technology to market. The current Edwards Lifesciences CSO was in on the ground floor of two of medtech's most disruptive treatments, stents and transcatheter aortic valve replacement.

On December 12th, Rowe will sit down with MassDevice editor Brad Perriello for a long ranging discussion about the inside story on how these technologies came to market and what Rowe learned along the way.


Register now with the code "TAVR" and save 15% today.

Speak Your Mind

*